The Molecule
In 1959, in a laboratory in Beerse, Belgium, a 33-year-old chemist named Paul Janssen synthesized a compound 50 to 100 times more potent than morphine. He called it fentanyl. His company, Janssen Pharmaceutica — founded just three years earlier — was acquired by Johnson & Johnson in 1961. The patent was filed in 1964.
Fentanyl was designed for a specific, narrow purpose: surgical anesthesia and severe pain management in hospital settings. It was a Schedule II controlled substance — legal, regulated, prescribed. For decades, it worked as intended.
The crisis did not begin with fentanyl. It began with a different opioid, a different company, and a different lie.
The Lie
In 1996, Purdue Pharma launched OxyContin — a time-release formulation of oxycodone. First-year sales: $48 million. By 2000: $1.1 billion. The growth was not organic. It was engineered.
Between 1996 and 2001, Purdue hosted over 40 all-expenses-paid conferences at resorts in Florida, Arizona, and California. More than 5,000 physicians, pharmacists, and nurses attended. The company increased its sales force by 73% in seven years. The message to every doctor: OxyContin is different. It’s safer. Fewer than 1% of patients become addicted.
I was advised by the manufacturer of OxyContin, through its employees and marketing materials, that OxyContin was less addictive, less prone to tolerance, and less prone to abuse than other opiates. — Physician testimony, DOJ proceedings
The “fewer than 1%” claim was based on a one-paragraph letter published in the New England Journal of Medicine in 1980 — the Porter & Jick letter. It was not a study. It was not peer-reviewed research. It was a brief correspondence about hospitalized patients receiving short-term, supervised opioid treatment. Purdue extrapolated this single paragraph to justify prescribing OxyContin for chronic outpatient pain.
The Reckoning
On May 10, 2007, Purdue Frederick — a Purdue Pharma affiliate — pled guilty to criminal misbranding of OxyContin. Three executives pled guilty individually. Fine: $634 million. The company admitted it had “fraudulently and misleadingly marketed OxyContin as less addictive.”
In 2020, Purdue Pharma itself pled guilty to two federal criminal charges: conspiracy to defraud the United States and violation of federal anti-kickback statutes.
In June 2024, the Supreme Court ruled 5–4 that the original bankruptcy plan improperly shielded the Sackler family from civil liability. In December 2024, a new settlement was reached: $7.4 billion total. The Sacklers will pay $6.5 billion over 15 years. Purdue will pay $900 million upfront.
The Arithmetic of Accountability
The Chain
The opioid epidemic followed a three-wave pattern documented by the CDC. Wave one (1990s): prescription opioid overprescription, driven by Purdue’s marketing. Wave two (2010): patients cut off from prescriptions turned to heroin. Wave three (2013): illicitly manufactured fentanyl — Paul Janssen’s molecule, now cooked in Mexican labs using Chinese precursor chemicals — flooded the street supply.
By 2023, synthetic opioids (primarily illicit fentanyl) accounted for 72,776 of 105,007 total drug overdose deaths in the United States. Nearly 70% of cocaine-involved deaths also involved fentanyl. The molecule designed for surgical suites in 1960 became the leading killer in the unregulated drug market.
The Ledger
While 806,000 Americans died from opioids — a crisis with clear pharmaceutical origins — the federal government spent over $1 trillion on the War on Drugs since 1971. The federal drug control budget grew from $81 million in 1969 to an estimated $41 billion in 2022 — a 1,090% increase adjusted for inflation.
Today, 44–46% of federal prisoners are incarcerated for drug offenses. That is roughly 89,000 people out of approximately 154,000. Drug offenses are the single largest category in the federal prison system. Across all facilities — federal, state, and local — an estimated 361,000 people are incarcerated for drugs.
The Sackler family is not among them.
← Back to Issue 06